The World's Most Advanced ADM for Wounds

Dermacell AWM is a technologically advanced human acellular dermal matrix that is decellularized using Matracell®, a proprietary, patented, and validated processing technology. Matracell removes a minimum of 97% of donor DNA1, allowing for rapid cellular infiltration and re-vascularization. Dermacell AWM is terminally sterilized, ready to use without refrigeration or re-hydration.

image®, a proprietary, patented, and validated processing technology" class="mx-3" height="60" src="https://www.lifenethealth.org/sites/default/files/images/Dermacell_icons-1.png" width="60" />

Biohospitable: All cells ≥ 97% donor DNA removed to potentially minimize any adverse patient response.

image®, a proprietary, patented, and validated processing technology" class="mx-3" height="60" src="https://www.lifenethealth.org/sites/default/files/images/Dermacell_icons-2.png" width="60" />

Intact Acellular Framework: Retains native growth factors, collagen and elastin.

image®, a proprietary, patented, and validated processing technology" class="mx-3" height="60" src="https://www.lifenethealth.org/sites/default/files/images/Dermacell_icons-3.png" width="60" />

Room Temperature Storage: Ready to use out of the package (15°C- 30°C).

image®, a proprietary, patented, and validated processing technology" class="mx-3" height="60" src="https://www.lifenethealth.org/sites/default/files/images/Dermacell_icons-4.png" width="60" />

Proven: Conducted the largest randomized controlled trial (RCT) to date using hADM in chronic wounds.2

Clinical Applications

  • Chronic wounds such as diabetic foot ulcers (DFUs), venous stasis ulcers (VSUs), arterial ulcers and pressure ulcers, as well as dehisced surgical wounds and traumatic burns
  • Dermacell AWM can be used over exposed tendon, bone, joint capsule, and muscle

image®, a proprietary, patented, and validated processing technology" data-entity-type="file" data-entity-uuid="5f4b3827-3109-4afb-a26f-4915a1e79327" height="229" src="//dev-lifenethealth.eastus.cloudapp.azure.com/cdn/ff/tkt_6wnr4JRHQpYt6kEWylv76EXFGmZIouhRsbkyqgY/1636619510/public/product/Dermacell_icons_wounds-1(2).png" width="229" />image®, a proprietary, patented, and validated processing technology" data-entity-type="file" data-entity-uuid="591d0570-ef65-4f66-90e4-40c19805e408" height="226" src="//dev-lifenethealth.eastus.cloudapp.azure.com/cdn/ff/tkt_6wnr4JRHQpYt6kEWylv76EXFGmZIouhRsbkyqgY/1636619510/public/product/Dermacell_icons_wounds-2(1).png" width="226" />

1. Moore MA, Samsell B, Wallis G, Triplett S, Chen S, Linthurst Jones A, Qin X. Decellularization of human dermis using non-denaturing anionic detergent and endonuclease: a review. Cell Tissue Bank. 2015;16(2):249-259.

2. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017. 25(3):483-497.